Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant DC Vaccine for Resected Monosomy 3 Uveal Melanoma
NCT01983748Phase 3Completed
- Sponsor
- University Hospital Erlangen
- Start
- Aug 2014
- Primary completion
- Aug 2024
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of Autologous dendritic cells loaded with autologous tumor RNA in Uveal melanoma (UM), sponsored by University Hospital Erlangen. Started Aug 2014; status: completed.
02
Drugs
Autologous dendritic cells loaded with autologous tumor RNA
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT01983748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01983748.